Jazz Pharmaceuticals plc Stockholders Equity

Quick Answer

Jazz Pharmaceuticals plc reported Stockholders Equity of $4.32 billion for the year ending 2025.

  • Jazz Pharmaceuticals plc showed an increase of +5.5% in Stockholders Equity from 2024 to 2025.
  • This data is from Jazz Pharmaceuticals plc's annual report (Form 10-K), filed with the SEC on February 24, 2026.
  • XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Quarterly values from 10-Q filings: Q1 2013: $1.16 billion | Q2 2013: $1.18 billion | Q3 2013: $1.24 billion | Q1 2014: $1.25 billion | Q2 2014: $1.28 billion | Q3 2014: $1.34 billion | Q1 2015: $1.31 billion | Q2 2015: $1.45 billion | Q3 2015: $1.56 billion | Q4 2015: $1.71 billion | Q1 2016: $1.71 billion | Q2 2016: $1.80 billion | Q3 2016: $1.83 billion | Q1 2017: $1.98 billion | Q2 2017: $2.20 billion | Q3 2017: $2.47 billion | Q1 2018: $2.79 billion | Q2 2018: $2.87 billion | Q3 2018: $3.03 billion | Q1 2019: $2.73 billion | Q2 2019: $2.98 billion | Q3 2019: $3.05 billion | Q1 2020: $2.81 billion | Q2 2020: $3.14 billion | Q3 2020: $3.38 billion | Q1 2021: $3.80 billion | Q2 2021: $4.13 billion | Q3 2021: $3.94 billion | Q1 2022: $3.61 billion | Q2 2022: $3.20 billion | Q3 2022: $2.75 billion | Q1 2023: $3.34 billion | Q2 2023: $3.53 billion | Q3 2023: $3.49 billion | Q1 2024: $3.70 billion | Q2 2024: $3.76 billion | Q3 2024: $4.17 billion | Q1 2025: $4.17 billion | Q2 2025: $3.71 billion | Q3 2025: $3.96 billion.
  • Over the full 18 years of available data (2008 to 2025), Jazz Pharmaceuticals plc's Stockholders Equity has grown by 4,749.7%.
  • Historical annual values: Fiscal year 2025: $4.32 billion | Fiscal year 2024: $4.09 billion | Fiscal year 2023: $3.74 billion | Fiscal year 2022: $3.09 billion | Fiscal year 2021: $3.97 billion | Fiscal year 2020: $3.66 billion | Fiscal year 2019: $3.11 billion | Fiscal year 2018: $2.76 billion | Fiscal year 2017: $2.71 billion | Fiscal year 2016: $1.88 billion | Fiscal year 2015: $1.60 billion | Fiscal year 2014: $1.37 billion | Fiscal year 2013: $1.30 billion | Fiscal year 2012: $1.12 billion | Fiscal year 2011: $192.79 million | Fiscal year 2010: $30.55 million | Fiscal year 2009: -$72.83 million | Fiscal year 2008: -$92.88 million.
  • Data sourced from SEC EDGAR public filings as of August 6, 2026.

Last verified: